EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Apolipoprotein A5 reduces clearance of VLDL by altering apolipoprotein E content

Pheruza Tarapore, Debi Swertfeger, Jamie Morris, Yi He, Snigdha Sarkar, John T Melchior, Amy S Shah, Min Liu, W Sean Davidson

Journal of Lipid Research · 2025

DOI: 10.1016/j.jlr.2025.100917 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Lipid Research, 2025. Verfasst von Pheruza Tarapore und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, University of Cincinnati, Cincinnati, OH, USA. Hauptthemen laut MEDLINE: Apolipoprotein A-V, Lipoproteins, VLDL, Apolipoproteins E. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NHLBI NIH HHS, National Institute of Neurological Disorders and Stroke.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Apolipoprotein A-V (APOA5) is a critical regulator of circulating triglyceride (TG) levels. Its deletion leads to elevated plasma TG concentrations by altering the metabolism of VLDL particles in vivo. One way APOA5 exerts its effects is through the modulation of LPL activity, specifically by disrupting inhibitory interactions between LPL and angiopoietin-like proteins (ANGPTLs). However, the impact of APOA5 on VLDL composition and its potential to alter VLDL metabolism in other ways remains poorly understood. To address this, we investigated the influence of APOA5 on the VLDL proteome, LPL activation, and hepatic remnant uptake. Using VLDL from Apoa5 KO and WT mice, we found no evidence that APOA5 directly enhances LPL activity in purified or plasma systems. However, VLDL from Apoa5 KO mice was cleared significantly more slowly by cultured hepatocytes. VLDL proteomics experiments from two independent laboratories identified altered contents of 23 proteins involved in lipoprotein metabolism, inflammation, and immune response in Apoa5 KO VLDL, including reductions in APOE and serum amyloid A1. Remarkably, reintroduction of recombinant mouse APOA5 to the KO plasma partially restored the WT VLDL proteome, including APOE, and normalized VLDL uptake by hepatocytes without altering LPL lipolysis. These findings reveal that APOA5 influences hepatic clearance of VLDL remnants by modulating particle composition, particularly APOE content. This study expands the functional scope of APOA5 in TG metabolism and underscores its role in VLDL remodeling and remnant clearance, offering new insights with implications for understanding hypertriglyceridemia and its roles in inflammation and immune response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Apolipoprotein A-VLipoproteins, VLDLApolipoproteins EAnimalsMiceMice, KnockoutMaleHepatocytesMice, Inbred C57BLHumansTriglycerides

Stichwörter der Autor:innen

LPLMSVLDLapolipoproteinapolipoprotein A-Vapolipoprotein Elipolysisstructuretriglyceride-rich

Substanzen

Apolipoprotein A-VLipoproteins, VLDLApolipoproteins EApoa5 protein, mouseTriglycerides

Autor:innen und Institutionen

  • Department of Pathology and Laboratory Medicine, University of Cincinnati, Cincinnati, OH, USA.
  • Department of Pediatrics, Cincinnati Children's Hospital Medical Center and the University of Cincinnati, Cincinnati, OH, USA.
  • Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA.
  • Biological Sciences Division, Earth and Biological Sciences Directorate, Pacific Northwest National Laboratory, Richland, WA, USA.
  • Department of Pathology and Laboratory Medicine, University of Cincinnati, Cincinnati, OH, USA; Biological Sciences Division, Earth and Biological Sciences Directorate, Pacific Northwest National Laboratory, Richland, W…
  • Department of Pathology and Laboratory Medicine, University of Cincinnati, Cincinnati, OH, USA. Electronic address: Davidswm@ucmail.uc.edu.

Förderung

  • NINDS NIH HHS
  • NHLBI NIH HHS
  • National Institute of Neurological Disorders and Stroke
  • National Heart Lung and Blood Institute

Zitieren

APA

Tarapore, P., Swertfeger, D., Morris, J., He, Y., Sarkar, S., Melchior, J. T., Shah, A. S., Liu, M., & Davidson, W. S. (2025). Apolipoprotein A5 reduces clearance of VLDL by altering apolipoprotein E content. Journal of Lipid Research. https://doi.org/10.1016/j.jlr.2025.100917

Vancouver

Tarapore P, Swertfeger D, Morris J, He Y, Sarkar S, Melchior JT, et al. Apolipoprotein A5 reduces clearance of VLDL by altering apolipoprotein E content. Journal of Lipid Research. 2025. doi:10.1016/j.jlr.2025.100917

BibTeX
@article{Tarapore2025,
  author = {Tarapore, Pheruza and Swertfeger, Debi and Morris, Jamie and He, Yi and Sarkar, Snigdha and Melchior, John T and Shah, Amy S and Liu, Min and Davidson, W Sean},
  title = {Apolipoprotein A5 reduces clearance of VLDL by altering apolipoprotein E content},
  journal = {Journal of Lipid Research},
  year = {2025},
  doi = {10.1016/j.jlr.2025.100917}
}
Kostenlos starten →